Navigation Links
China-Biotics Appoints New Chief Operating Officer

SHANGHAI, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics" or "the Company"), (Nasdaq: CHBT) the leading developer, manufacturer and distributor of probiotics products in China, today announced the appointment of Dr. Hui S. Chang as Chief Operating Officer, effective immediately.

Dr. Chang brings 15 years of biopharmaceutical project management experience and excellent research capabilities. Prior to joining China-Biotics, Dr. Chang served as the president of a consulting service for a Sino-U.S. joint biopharmaceutical program, where he led the scientific design, development, clinical trials, production and quality control for viral vaccines and antibodies. He reported to the State Administration of Foreign Experts Affairs and played a key role in generating profits on the completed contract. Dr. Chang was previously a senior manager of Nabi Biopharmaceuticals, where he supervised the development and production of bacterial and viral vaccines, developed biological potency and immunological methods and managed the development of assays for quality control and clinical testing. Earlier, Dr. Chang served as a manager at Vaccinnate, a North American bio-vaccine company, where he led the design, GMP production and clinical testing of viral vaccines. Previously, Dr. Chang was a research scientist with Cambridge Biotech, where he specialized in the production and quality control of monoclonal biological products, protein products as well as HIV and HTLV antigen. Dr. Chang started his professional career at North AM VAC Inc. in 1989.

Dr. Chang holds a Ph.D. in vaccine development focusing on biochemistry and immunology as well as an MBA with concentration in finance and logistics in the vaccine industry from Johns Hopkins University. He also has a Bachelor of Science in biology from the University of Maryland. Dr. Chang has also received certified training in Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and Good Safety Practice (GSP) procedures. Dr. Chang is fluent in English and mandarin Chinese.

Mr. Jinan Song, Chairman and CEO of China-Biotics, commented, "We are very pleased that China-Biotics has been able to attract such a qualified candidate for this crucial position. Dr. Chang's solid biotech background, advanced project management track record, and his excellent knowledge in business and finance will make him a strong COO and desirable addition to our team. China-Biotics continues to build a strong management team to support our expanding bulk business in both the dairy and animal feed markets in China."

About China-BioticsChina-Biotics, Inc. ("China-Biotics" or "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering (Shanghai) Co. Ltd., the Company develops and produces its proprietary product portfolio. Currently, the retail products are sold OTC mainly through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. The Company also sells bulk products to institutional customers such as dairy and animal feed producers, as well as pharmaceutical companies. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit .Contact:Travis Cai Chief Financial OfficerChina-Biotics, Inc.traviscai@chn-biotics.comShiwei Yin/Dixon Chen

SOURCE China-Biotics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics to Report Fiscal Year 2011 Second Quarter Financial Results on November 9
2. China-Biotics Hosted its First Investor Day Event
3. China-Biotics Ranked Number 62 on FORTUNES 100 Fastest-Growing Companies List
4. China-Biotics to Report Fiscal Year 2011 First Quarter Financial Results on August 9
5. China-Biotics Provides Further Updates on Qingpu New Facility
6. China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010
7. China-Biotics to Report Fourth Quarter and Fiscal Year 2010 Financial Results on June 11
8. China-Biotics to Present at Bank of America Merrill Lynch Healthcare Event on June 22
9. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
10. China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor
11. China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing of ... team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... sale of broadly enabling, pressure cycling technology ("PCT")-based sample ... announced it has received gross proceeds of $745,000 from ... (the "Offering"), increasing the total amount raised to date ... closings are expected in the near future. ...
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):